| Literature DB >> 15452340 |
Zhengrong Zhu1, Sean Kim, Taosheng Chen, Jun-Hsiang Lin, Aneka Bell, James Bryson, Yves Dubaquie, Ning Yan, Joseph Yanchunas, Dianlin Xie, Robert Stoffel, Michael Sinz, Kenneth Dickinson.
Abstract
Pregnane X receptor (PXR) transactivation and binding assays have been developed into high-throughput assays, which are robust and reproducible (Z' > 0.5). For most compounds, there was a good correlation between the results of the transactivation and binding assays. EC(50) values of compounds in the transactivation assay correlated reasonably well with their IC(50) values in the binding assay. However, there were discrepancies with some compounds showing high binding affinity in the binding assay translated into low transactivation. The most likely cause for these discrepancies was an agonist-dependent relationship between binding affinity and transactivation response. In general, compounds that bound to human PXR and transactivated PXR tended to be large hydrophobic molecules.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15452340 DOI: 10.1177/1087057104264902
Source DB: PubMed Journal: J Biomol Screen ISSN: 1087-0571